20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Alamar Biosciences, Inc. Common Stock (ALMR) operates in the MEDICAL DEVICES industry and is headquartered in Fremont, United States with about 286 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, ALMR reported $74M in revenue and ($30M) in net income.
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers.
Interactive charts & full statements → Open the ALMR valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Total Revenue | $85M | $74M | $25M |
| Gross Profit | $47M | $42M | $9M |
| Gross Margin % | 55.6% | 56.2% | 34.2% |
| Operating Income (EBIT) | ($42M) | ($31M) | ($50M) |
| Operating Margin % | -50.0% | -42.2% | -197.2% |
| Net Income | ($49M) | ($30M) | ($47M) |
| Net Margin % | -58.1% | -40.2% | -187.2% |
| EBITDA | — | ($25M) | — |
| Earnings Per Share (EPS) | — | $-0.45 | $-0.71 |
| Shares Outstanding (M) | 59M | 67M | 67M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Total Revenue | $29M | $26M | $16M | $13M |
| Gross Profit | $18M | $14M | $9M | $6M |
| Gross Margin % | 60.2% | 55.5% | 53.1% | 48.8% |
| Operating Income (EBIT) | ($14M) | ($12M) | ($8M) | ($9M) |
| Operating Margin % | -46.0% | -47.4% | -49.0% | -65.3% |
| Net Income | ($13M) | ($21M) | ($7M) | ($8M) |
| Net Margin % | -44.9% | -81.9% | -43.5% | -58.5% |
| EBITDA | ($13M) | ($19M) | — | — |
| Earnings Per Share (EPS) | $-0.22 | $-0.31 | — | — |
| Shares Outstanding (M) | 59M | 69M | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Cash from Operations (CFO) | ($57M) | ($54M) | ($55M) |
| Capital Expenditures (CapEx) | $6M | $6M | $3M |
| Free Cash Flow (FCF) | ($63M) | ($60M) | ($59M) |
| FCF Margin % | -74.3% | -80.8% | -233.1% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Cash from Operations (CFO) | ($11M) | ($20M) | ($12M) | ($13M) |
| Capital Expenditures (CapEx) | $4M | $1M | $1M | $1M |
| Free Cash Flow (FCF) | ($15M) | ($21M) | ($13M) | ($14M) |
| FCF Margin % | -50.8% | -80.5% | -80.4% | -107.3% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Total Assets | $391M | $140M | $150M |
| Cash & Cash Equivalents | $133M | $30M | $27M |
| Total Liabilities | $78M | $299M | $283M |
| Total Debt (Short + Long-Term) | $12M | $12M | $2M |
| Total Shareholders' Equity | $313M | ($159M) | ($133M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ALMR viewer.
About TickerBase · Data methodology & sources · Privacy · Terms